Multiple radiopharmaceuticals in the development pipeline are showing real promise in the realms of oncology, neurology and cardiology.

The operative phrase for PET reimbursement circa 2013 may be “cautiously optimistic.”

The right dose to the right patient at the right time is the mantra. But tracking dose is gaining in popularity among physicians and patients.

Many physicians and patients cast staging breast MRI as an imperfect exam. From the physician’s perspective, the exam generates thousands of difficult-to-interpret images. False-positive findings are not uncommon.

What nuclear medicine is now to presurgical planning, optical molecular imaging may soon become to intraoperative tumor removal.

Multiple radiopharmaceuticals in the development pipeline are showing real promise in the realms of oncology, neurology and cardiology. 

The National Football League (NFL) will pay more than $750 million to settle a lawsuit brought by retired players who argued the league didn’t do enough to protect players from concussions, according to the terms of a tentative settlement announced Aug. 29.

Molecular imaging headlines are often dominated by applications in oncology and cognitive disorders. The breadth of information that can be gleaned from molecular imaging is actually much wider, as evidenced by some of this month’s top stories.